Prodrug derivatives of substituted triazolopyridines

US9586958B2 · kind B2 · utility

Assignee

• Bayer Pharma Aktiengesellschaft · DE

Inventors

• Volker Schulze · Hohen Neuendorf, DE
• Hans-Georg Lerchen · Leverkusen, DE
• Donald Bierer · Daly City, US
• Antje Margret Wengner · Berlin, DE
• Gerhard Siemeister · Berlin, DE
• Philip Lienau · Berlin, DE
• Ursula Krenz · Leichlingen, DE
• Dirk Kosemund · Berlin, DE
• Detlef STÖCKIGT · Potsdam, DE
• Michael Brüning
• Ulrich Lücking · Berlin, DE
• Ildiko Terebesi · Berlin, DE

Key dates

• Filing date: Jun 6, 2014
• Grant date: Mar 7, 2017
• Expiry date: Jun 6, 2034

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K38/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to prodrug derivatives of Mps-1 kinase inhibitors, processes for their preparation, and their use for the treatment and/or prophylaxis of diseases.